Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Enrolling by invitation × NET × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Recruiting 12 Completed 10 Unknown 6 Terminated 4 Withdrawn 2 Suspended 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5 CNS 4 Other solid neoplasm 3 Breast 3 Thoracic 2 Genitourinary 2 Tumor-Agnostic 1 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 NET 1 Lymphoid 1 Head & Neck 1 Endocrine 1 Dermatologic 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

irinotecan sucrosofate 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

National Health Research Institutes, Taiwan

Phase 1/2 Enrolling by invitation

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡